RCM
NTLA icon

RA Capital Management’s Intellia Therapeutics NTLA Stock Holding History

RA Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$76.6M Buy
+4,526,926
New +$63.4M 0.67% 30
2021
Q3 		– Sell
-15,000
Closed -$2.43M – 103
2021
Q2 		$2.43M Buy
+15,000
New +$1.17M 0.04% 89

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RA Capital Management's NTLA Position: Q2 2026 in Review

RA Capital Management opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 4,526,926 shares worth $76.6M. The stake represents 0.67% of the portfolio and ranks #30 among its holdings. This is a return to the name: RA Capital Management previously reported a position in NTLA as recently as Q2 2021.

RA Capital Management first reported a position in NTLA in Q2 2021 and has held it in 2 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • RA Capital Management held 4,526,926 shares of Intellia Therapeutics worth $76.6M as of Q2 2026.
  • Intellia Therapeutics was a new RA Capital Management position in Q2 2026.
  • Intellia Therapeutics made up 0.67% of RA Capital Management's portfolio in Q2 2026, its #30 holding.
  • RA Capital Management first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 2 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on RA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.